TEL AVIV, Israel, Dec. 20, 2021 /PRNewswire/ -- Chemomab
Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage
biotechnology company focused on the discovery and development of
innovative therapeutics for fibrotic and inflammatory diseases with
high unmet need, today announced that senior management will
participate in the LifeSci Partners 11th Annual
Corporate Access Event, which will be held virtually
from January 5-7, 2022, and the H.C. Wainwright
BioConnect Conference, which will be held virtually from
January 10-13, 2022.
Event details are below:
LifeSci Partners 11th Annual Corporate Access
Event
Date:
January
5-7, 2022
Format:
1-on-1 virtual meetings with senior management
Registration: LifeSci Partners Corporate
Access Event 2022
HC Wainwright BioConnect 2022 Virtual Healthcare
Conference
Date:
Webcast
available on demand at 7:00am ET
Jan.10 through Jan.13, 2022
Format:
Corporate overview webcast
Registration:
https://journey.ct.events/view/9e85b478-28c8-4b98-9959-d900bd47a369
Replay:
Available on Chemomab website starting Jan.14, 2022 at
investors.chemomab.com/events
About Chemomab Therapeutics Ltd.
Chemomab is a
clinical-stage biotechnology company focusing on the discovery and
development of innovative therapeutics for fibrotic and
inflammatory diseases with high unmet need. Based on the unique and
pivotal role of the soluble protein CCL24 in promoting fibrosis and
inflammation, Chemomab developed CM-101, a monoclonal antibody
designed to bind and block CCL24 activity. CM-101 has demonstrated
the potential to treat multiple severe and life-threatening
fibrotic and inflammatory diseases. It is currently in two Phase 2
safety and efficacy trials—one in patients with primary sclerosing
cholangitis and the second in patients with liver fibrosis, with a
third Phase 2 trial in systemic sclerosis expected to begin early
in 2022.
For more information on Chemomab, visit chemomab.com.
Contacts:
Investor Relations:
Irina Koffler
LifeSci Advisors, LLC
Phone: +1-917-734-7387
ir@chemomab.com
Media:
Barbara
Lindheim
Chemomab Therapeutics
Consulting Vice President
Investor & Public Relations, Strategic Communications
barbara@chemomab.com
View original
content:https://www.prnewswire.com/news-releases/chemomab-to-participate-in-lifesci-partners-annual-corporate-access-event-and-hc-wainwright-bioconnect-2022-healthcare-conference-301448086.html
SOURCE ChemomAb Ltd.